Nemesis Bioscience Ltd announced today that it had reached an agreement on terms for a two-year research collaboration with Shionogi & Co. Ltd. to further develop Nemesis Transmid Technology© for the treatment and/or prevention of hard-to-treat respiratory infections caused by Pseudomonas...
Read article
On 19 June, one of AberInnovation's newest members, Nemesis Bioscience, announced the completion of a seed funding round of £1.4m from a syndicate of new investors including Shionogi & Co Ltd, Coastal International Holdings and Wren Capital in addition to existing investors the...
Read articleFollow Us
Latest Tweet
